End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies
Figures
Figure 1 with 1 supplement
Figure 1—figure supplement 1
Figure 2 with 2 supplements
Figure 2—figure supplement 1
Figure 2—figure supplement 2
Figure 3 with 2 supplements
Figure 3—figure supplement 1
Figure 3—figure supplement 2
Figure 4
Figure 5
Videos
Video 1
Additional files
-
Supplementary file 1
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp1-v2.docx
-
Supplementary file 2
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp2-v2.xlsx
-
Supplementary file 3
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp3-v2.xlsx
-
Transparent reporting form
- https://cdn.elifesciences.org/articles/71335/elife-71335-transrepform1-v2.pdf
-
Source data 1
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp4-v2.xlsx
-
Source data 2
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp5-v2.pdf
-
Source data 3
- https://cdn.elifesciences.org/articles/71335/elife-71335-supp6-v2.pdf
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies
eLife 10:e71335.
https://doi.org/10.7554/eLife.71335